

09/781891

Search results

# Freeform Search

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
**Database:** EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

**Term:** L9 and (assay\$ or detect\$ or identif\$) near10  
 (variant\$ or muta\$) near5 (HBV or hepatitis near B)

**Display:** 100 Documents in Display Format: - Starting with Number 1

**Generate:**  Hit List  Hit Count  Side by Side  Image

**Search** **Clear** **Interrupt**

## Search History

**DATE:** Tuesday, February 15, 2005 [Printable Copy](#) [Create Case](#)

<b>Set Name</b>	<b>Query</b>	<b>Hit Count</b>	<b>Set Name</b>
			result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L11	L9 and (assay\$ or detect\$ or identif\$) near10 (variant\$ or muta\$) near5 (HBV or hepatitis near B)	29	<u>L11</u>
L10	L9 and (variant\$ or muta\$) near5 (HBV or hepatitis near B)	47	<u>L10</u>
L9	L6 and hepatocyte\$	51	<u>L9</u>
L8	L1 and (detect\$ or assay\$ or identif\$) near10 (variant\$ or muta\$ or alter\$) near10 (HBV or hepatitis near B)	6	<u>L8</u>
L7	L2 and (detect\$ or assay\$ or identif\$) near10 (variant\$ or muta\$ or alter\$) near10 (HBV or hepatitis near B)	4	<u>L7</u>
L6	(HBV or hepatitis near B) near20 (variant\$ or muta\$) near10 (polymerase or HbsAg or core near promoter\$)	162	<u>L6</u>
L5	L2 and (detect\$ or identif\$) near10 (variant\$ or muta\$) near10 (HBV or hepatitis near B)	4	<u>L5</u>
L4	L2 and (variant\$ or muta\$)	26	<u>L4</u>
L3	L2 and variant\$	17	<u>L3</u>
L2	(HBV or hepatitis near B near virus\$) near10 (baculovir\$ or nuclear near polyhedrosis)	39	<u>L2</u>

L1 (HBV or hepatitis near B near virus\$) and (baculovir\$ or nuclear near polyhedrosis)

4193 L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)

## Search Results - Record(s) 1 through 51 of 51 returned.

- 
1. 20040209292. 20 Jan 04. 21 Oct 04. Mutant human hepatitis B viral strain and uses thereof. Oon, Chong Jin, et al. 435/6; C12Q001/68.
2. 20040194155. 01 Oct 03. 30 Sep 04. HBV mutations associated with reduced susceptibility to adefovir. Delaney, William E., et al. 800/8; 435/320.1 435/325 800/9 A01K067/00 A01K067/033 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02.
3. 20040191763. 01 Oct 03. 30 Sep 04. HBV mutations associated with reduced susceptibility to adefovir. Delaney, William E., et al. 435/5; 435/235.1 435/320.1 435/325 435/456 435/69.3 536/23.72 800/9 C12Q001/70 A01K067/00 C07H021/04 C12N007/00 C07K014/02 C12N015/86.
4. 20040127446. 23 Sep 03. 01 Jul 04. Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication. Blatt, Lawrence, et al. 514/44; 536/23.72 A61K048/00 C07H021/02.
5. 20040110143. 09 Dec 02. 10 Jun 04. Modulation of fetoprotein transcription factor expression. Bennett, C. Frank, et al. 435/6; 514/44 536/23.5 C12Q001/68 C07H021/04 A61K048/00.
6. 20040106539. 30 Oct 03. 03 Jun 04. Agents for the treatment of viral infections. Schubert, Ulrich, et al. 514/2; A61K038/00.
7. 20040054156. 15 Jan 03. 18 Mar 04. Method and reagent for inhibiting hepatitis B viral replication. Draper, Kenneth, et al. 536/23.1; 424/93.21 435/366 C07H021/02 C12N005/08 A61K048/00.
8. 20040047879. 28 Jul 03. 11 Mar 04. Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof. Tian, Bo, et al. 424/189.1; 530/350 C07K014/02 A61K039/29.
9. 20040029110. 04 Jun 03. 12 Feb 04. Method for typing and detecting HBV. Stuyver, Lieven, et al. 435/5; 435/6 C12Q001/70 C12Q001/68.
10. 20040005541. 12 May 03. 08 Jan 04. Hepatitis b virus dna polymerase and surface antigen variants and methods of using same. Bartholomeusz, Angeline Ingrid, et al. 435/5; 435/235.1 C12Q001/70 C12N007/00.
11. 20030229225. 12 May 03. 11 Dec 03. Novel phosphonic acid based prodrugs of PMEA and its analogues. Reddy, K. Raja, et al. 544/244; C07F009/6512.
12. 20030203969. 07 Jan 03. 30 Oct 03. Pharmaceutically active aromatic guanylhydrazones. Bevec, Dorian, et al. 514/597; 514/619 514/620 514/634 564/147 564/237 564/51 A61K031/17 A61K031/165 A61K031/155 C07C279/18.
13. 20030162741. 28 Feb 03. 28 Aug 03. Oral DNA composition for hepatitis B virus chronic infection. Ng, Mun-Hon, et al. 514/44; 424/93.2 A61K048/00.
14. 20030129202. 16 Dec 02. 10 Jul 03. Mutated hepatitis b virus, its nucleic and protein constituents and uses thereof. Trepo, Christian, et al. 424/225.1; 424/186.1 435/235.1 435/320.1 435/325

435/5 435/6 435/69.3 530/388.3 536/23.72 C12Q001/70 C07H021/04 A61K039/12 C12N007/00  
C12P021/02 C12N005/06 C07K016/08 C12Q001/68 C12N015/09 A61K039/29 C12N007/01  
C12N015/00 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02 C07K016/00  
C12P021/08.

- 
15. 20030096222. 02 Feb 01. 22 May 03. Assay. Delaney, William IV, et al. 435/5; 435/6  
C12Q001/70 C12Q001/68.
- 
16. 20030083306. 15 Jun 01. 01 May 03. 3'-prodrugs of 2'-deoxy-beta-L-nucleosides. Imbach,  
Jean-Louis, et al. 514/45; 514/46 514/49 514/50 536/27.2 536/27.3 536/28.4 A61K031/7076  
A61K031/7068 C07H019/16 C07H019/06.
- 
17. 20030068301. 08 Jun 01. 10 Apr 03. Method and reagent for inhibiting hepatitis B virus  
replication. Draper, Kenneth, et al. 424/85.6; 424/85.7 514/44 536/23.1 A61K038/21 C07H021/02  
A61K048/00.
- 
18. 20030039957. 27 Nov 01. 27 Feb 03. Functional protein expression for rapid cell-free  
phenotyping. McCarthy, Laurence, et al. 435/5; 435/6 435/7.1 435/7.32 C12Q001/70 C12Q001/68  
G01N033/53 G01N033/554 G01N033/569.
- 
19. 20030003111. 31 Jul 02. 02 Jan 03. Mutant human hepatitis B viral strain and uses thereof.  
Oon, Chong Jin, et al. 424/227.1; 424/204.1 435/5 435/69.1 530/300 C12Q001/70 C12P021/06  
A61K039/12 A61K039/29 C07K002/00 C07K004/00 C07K005/00 C07K007/00 C07K014/00  
C07K016/00 C07K017/00 A61K038/00.
- 
20. 20020076446. 18 Jul 01. 20 Jun 02. Novel medicinal herbal composition for treating liver  
diseases and HIV. Wu, Tzu-Sheng. 424/551; 424/728 424/741 424/756 424/765 424/773 A61K035/78  
A61K035/38.
- 
21. 20020035085. 29 May 01. 21 Mar 02. Methods of treating hepatitis delta virus infection with  
beta-1-2'-deoxy-nucleosides. Sommadossi, Jean-Pierre, et al. 514/45; 514/46 514/47 514/48 514/50  
514/51 A61K031/7076 A61K031/7072.
- 
22. 6855346. 11 Jul 02; 15 Feb 05. Pharmaceutical composition having prophylactic effects on  
lamivudine-related disease relapse and drug resistance and methods of using the same. Wu; Tzu-Sheng.  
424/728; 424/725 424/741 424/773 424/777. A61K03578 A61K03537.
- 
23. 6787526. 26 Dec 02; 07 Sep 04. Methods of treating hepatitis delta virus infection with .beta.-  
L-2'-deoxy-nucleosides. Bryant; Martin L., et al. 514/45; 424/85.4 514/46 514/47 514/48 514/49 514/50  
514/894. A01N043/04 A61K031/70 A61K038/21.
- 
24. 6787142. 31 Jul 02; 07 Sep 04. Mutant human hepatitis B viral strain and uses thereof. Oon;  
Chong Jin, et al. 424/189.1; 424/184.1 424/185.1 424/227.1 435/5 435/6 435/7.1 435/8 530/300 530/350  
536/23.7 536/23.72 536/24.3 536/24.32. A61K039/29 A61K039/42 C07K014/00 C07K014/01  
C07K014/18.
- 
25. 6759193. 28 Jul 99; 06 Jul 04. Detection of human hepatitis B virus surface antigen mutants by  
specific amplification and its application on gene chip. Oon; Chong-Jin, et al. 435/6; 435/5 435/91.2  
536/23.72 536/24.3 536/24.33. C12Q001/68 C12Q001/70 C12P019/34.
- 
26. 6709812. 08 Oct 98; 23 Mar 04. Method for typing and detecting HBV. Stuyver; Lieven, et al.

435/5; 435/6 536/23.72 536/24.32. C12Q001/70 C12Q001/68 C12N015/36 C07H021/04.

---

- 27. 6610471. 05 Sep 00; 26 Aug 03. Methods and compositions to investigate infection by hepatitis B virus and agents to prevent and treat the infection. Isom; Harriet C., et al. 435/5; 435/370 435/69.1 436/820. C12Q001/70 G01N033/576.
- 28. 6596700. 29 May 01; 22 Jul 03. Methods of treating hepatitis delta virus infection with .beta.-L-2'-deoxy-nucleosides. Sommadossi; Jean-Pierre, et al. 514/45; 514/46 514/47 514/48 514/49 514/50 514/894. A01N043/04 A61K031/70.
- 29. 6569837. 14 Dec 01; 27 May 03. .beta.-L-2'-deoxy pyrimidine nucleosides for the treatment of hepatitis B. Gosselin; Gilles, et al. 514/45; 514/46 514/47 514/48 514/49 514/50 514/51 536/28.5 536/28.55. A61K031/70 C07H019/073.
- 30. 6566344. 14 Dec 01; 20 May 03. .beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B. Gosselin; Gilles, et al. 514/45; 514/46 514/47 514/48 514/49 514/50 514/51 536/28.5 536/28.51 536/28.52 536/28.53 536/28.54. A61K031/70 C07H019/06.
- 31. 6558675. 30 Apr 01; 06 May 03. Mutant human hepatitis B viral strain and uses thereof. Oon; Chong Jin, et al. 424/227.1; 424/185.1 424/189.1 424/202.1 514/44 536/22.1 536/23.7 536/23.72. A61K039/12 A61K039/29.
- 32. 6525242. 02 Nov 99; 25 Feb 03. Propagation of human hepatocytes in non-human mammals. Wu; George Y., et al. 800/8; 800/13 800/18 800/3 800/9. A01K067/00 A01K067/033 A01K067/027.
- 33. 6455078. 18 Jul 01; 24 Sep 02. Medicinal herbal composition for treating liver diseases and HIV. Wu; Tzu-Sheng. 424/725; 424/551 424/728 424/773 424/777 514/893 514/894. A61K035/78 A61K035/37 A61K035/38.
- 34. 6410009. 12 Nov 99; 25 Jun 02. Pharmaceutical composition for treating hepatitis B virus (HBV) infection. Galun; Eithan, et al. 424/85.2; 424/161.1 424/185.1 424/189.1 424/225.1 424/227.1 424/85.1 514/12 514/893 514/894 530/300 530/351. A61K045/05 A61K039/29 A61K038/20 C07K004/12 C07K014/54.
- 35. 6288033. 09 Oct 98; 11 Sep 01. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir. Leung; Ying-Kit. 514/12; 514/9 530/399. A61K038/12 A61K038/16 A61K038/22.
- 36. 6217858. 11 Feb 97; 17 Apr 01. Pharmaceutical composition for treating hepatitis B virus (HBV) infection. Galun; Eithan, et al. 424/85.2; 424/189.1 424/225.1 424/227.1 424/422. A61K045/05 A61K039/29 A61K038/20.
- 37. 6017536. 20 Dec 94; 25 Jan 00. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities. Barney; Shawn O'Lin, et al. 424/188.1; 424/208.1 530/300 530/324 530/325 530/326. A61K039/21.
- 38. 5981274. 18 Sep 96; 09 Nov 99. Recombinant hepatitis virus vectors. Tyrrell; D. Lorne J., et al. 435/320.1; 435/243 435/349 435/370. C12N015/86.
- 39. 5980901. 18 Sep 97; 09 Nov 99. Viral defective interfering particles and uses thereof. Shih; Chiaho, et al. 424/189.1; 424/188.1 424/204.1 424/225.1 424/227.1 424/93.6 435/235.1 435/236

435/320.1. A61K039/29 A61K039/12 C12N007/00 C12N007/04.

- 
40. 5939423. 16 Apr 97; 17 Aug 99. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir. Karlin; David Alan, et al. 514/263.31; 514/12 514/2. A61K031/52.
- 
41. 5925512. 23 May 95; 20 Jul 99. Hepatitis B virus mutants, reagents and methods for detection. Carman; William F., et al. 435/5; 435/7.92 436/518 436/820 530/387.9 530/388.3. C12Q001/70 G01N033/53 G01N033/543 G01N033/576.
- 
42. 5856087. 10 Oct 97; 05 Jan 99. Method for detecting immune response to hepatitis B. Thanavala; Yasmin, et al. 435/5; 435/69.3 514/14 530/326 530/328. C12Q001/70 C12P021/06 A61K038/00 A61K038/04.
- 
43. 5744135. 19 Jan 96; 28 Apr 98. Method of raising an immune response with an anti-idiotypic antibody having correspondence with human hepatitis B surface antigen. Thanavala; Yasmin, et al. 424/131.1; 424/149.1 514/14 530/387.2 530/388.3 530/389.4. A61K039/395 A61K038/03 C07K016/08 C07K016/42.
- 
44. 5668253. 05 Apr 95; 16 Sep 97. Peptide having antigenic properties similar to "a "determinant of hepatitis B surface antigen. Thanavala; Yasmin, et al. 530/326; 530/328. C07K007/04 C07K007/06 C07K014/005 C07K014/02.
- 
45. 5610050. 23 Apr 93; 11 Mar 97. Methods of preventing viral replication. Blum; Hubert E., et al. 435/238; 435/320.1 536/23.1 536/23.72 536/24.5. C12N007/06 C07H021/04.
- 
46. 5595739. 07 May 93; 21 Jan 97. Hepatitis B virus mutants, reagents and methods for detection. Carman; William F., et al. 424/189.1; 424/227.1 435/235.1 435/5 435/975 530/324 530/350 530/403 930/220. A61K039/29 G01N033/543 C07K014/02 C12Q001/70.
- 
47. 5593825. 23 May 95; 14 Jan 97. Hepatitis B virus mutants, reagents and methods for detection. Carman; William F., et al. 435/5; 435/252.3 435/254.11 435/320.1 435/325 435/352 435/362 435/367 435/69.3 435/975 536/23.72 536/24.32. C12Q001/70 C12N015/36.
- 
48. 5591440. 23 May 95; 07 Jan 97. Hepatitis B Virus mutants, reagents and methods for detection. Carman; William F., et al. 424/227.1; 435/235.1 435/325. A61K039/29 C12N007/00 C12N005/10.
- 
49. 5531990. 15 Dec 93; 02 Jul 96. Method of raising an immune response with an anti-idiotypic antibody having correspondence with human hepatitis B surface antigen. Thanavala; Yasmin, et al. 424/131.1; 424/149.1 514/14 530/387.2 530/388.3 530/389.4. A61K039/395 A61K038/03 C07K016/08 C07K016/42.
- 
50. 5378605. 08 Jun 93; 03 Jan 95. Method of detecting hepatitis B variants having deletions within the X region of the virus genome. Feitelson; Mark, et al. 435/5; 435/7.1 435/7.92 435/91.2. C12Q001/70 G01N033/53 C12P019/34.
- 
51. 4959462. 28 Jan 86; 25 Sep 90. Desoxyribonucleic acid; microorganisms; diagnostic agent for delta infection and the use thereof. Dijkema; Reinder, et al. 536/24.32; 435/320.1 435/6 436/501 436/811 436/813 536/24.3 536/25.32. C07H021/04 C12Q001/68 C12N015/00 G01N033/53.
-

[Generate Collection](#)[Print](#)

Terms	Documents
L6 and hepatocyte\$	51

[Prev Page](#)[Next Page](#)[Go to Doc#](#)